loader
Please Wait
Applying Filters...

Evonik Evonik

X

List of Momelotinib NDC API suppliers/manufacturers & exporters

Client Email Product
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 Cambrex Karlskoga AB (1)

filter

01 Momelotinib dihydrochloride monohydrate (1)

filter

01 U.S.A (1)

URL Supplier Web Content
Momelotinib dihydrochloride monohydrate
POWDER (1kg/kg)
BULK INGREDIENT
12651-123
2023-02-08
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for 1056634-68-4 / Momelotinib API manufacturers, exporters & distributors?

Momelotinib manufacturers, exporters & distributors 1

85

PharmaCompass offers a list of Momelotinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Momelotinib manufacturer or Momelotinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Momelotinib manufacturer or Momelotinib supplier.

PharmaCompass also assists you with knowing the Momelotinib API Price utilized in the formulation of products. Momelotinib API Price is not always fixed or binding as the Momelotinib Price is obtained through a variety of data sources. The Momelotinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Momelotinib

Synonyms

Cyt387, 1056634-68-4, Cyt-387, Cyt 387, N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide, Cyt 11387

Cas Number

1056634-68-4

Unique Ingredient Identifier (UNII)

6O01GMS00P

About Momelotinib

Momelotinib is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.

Momelotinib Manufacturers

A Momelotinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Momelotinib, including repackagers and relabelers. The FDA regulates Momelotinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Momelotinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Momelotinib Suppliers

A Momelotinib supplier is an individual or a company that provides Momelotinib active pharmaceutical ingredient (API) or Momelotinib finished formulations upon request. The Momelotinib suppliers may include Momelotinib API manufacturers, exporters, distributors and traders.

Momelotinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Momelotinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Momelotinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Momelotinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Momelotinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Momelotinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Momelotinib suppliers with NDC on PharmaCompass.

Momelotinib Manufacturers | Traders | Suppliers

Momelotinib Manufacturers, Traders, Suppliers 1
93

We have 1 companies offering Momelotinib

Get in contact with the supplier of your choice:

  1. Cambrex Corporation
Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Post Enquiry
POST ENQUIRY